Craig-Hallum analyst Alexander Nowak lowered the firm’s price target on Alimera Sciences to $8 from $18 to account for recent dilution, while keeping a Buy rating on the shares. While the quarter came in just below expectations, the firm thinks fundamentals are strong and positive forward commentary plus near breakeven in Q4 more than makes up for this modest miss.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ALIM:
- Alimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing ILUVIEN® in the Nordic Countries
- Alimera Sciences Announces 2022 Financial Results and Business Update
- Alimera Sciences reports Q4 EPS (54c) vs (59c) last year
- Alimera Sciences (ALIM) Q4 Earnings Cheat Sheet
- Alimera Sciences announces transactions to bolster balance sheet
